Epilepsy and migraine in a patient with Urbach–Wiethe disease  by Claeys, Kristl G. et al.
Seizure (2007) 16, 465—468
www.elsevier.com/locate/yseizCASE REPORT
Epilepsy and migraine in a patient with
Urbach—Wiethe disease
Kristl G. Claeys a,b,*,1, Lieve R.F. Claes a,1, Johan W.M. Van Goethem c,
Sandy Sercu d, Joseph Merregaert d, Julien Lambert e, Eric A. Van Marck f,
Paul M. Parizel c, Peter De Jonghe a,baNeurogenetics Group, Department of Molecular Genetics, Flanders Interuniversity Institute for
Biotechnology (VIB), University of Antwerp, Universiteitsplein 1, B-2610 Antwerpen, Belgium
bDepartment of Neurology, University Hospital Antwerp, Wilrijkstraat 10, B-2650 Antwerpen, Belgium
cDepartment of Radiology, Neuroradiology Section, University Hospital Antwerp, Wilrijkstraat 10, B-2650
Antwerpen, Belgium
d Laboratory of Molecular Biotechnology, Department of Biomedical Sciences, University of Antwerp,
Universiteitsplein 1, B-2610 Antwerpen, Belgium
eDepartment of Dermatology, University Hospital Antwerp, Wilrijkstraat 10, B-2650 Antwerpen, Belgium
f Laboratory of Pathology, Faculty of Medicine, University of Antwerp, Universiteitsplein 1, B-2610
Antwerpen, Belgium






Summary We report the clinical, neuroradiological, and molecular genetic findings
in a patient with lipoid proteinosis or Urbach—Wiethe disease. Interestingly, in this
patient epilepsy and migraine were the symptoms leading to the diagnosis of the
disease, contrary to most patients in whom skin abnormalities are the first recognized
symptoms.
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Lipoid proteinosis (LP) or Urbach—Wiethe disease,13
is a rare autosomal recessive disorder, characterized
by laryngeal infiltration leading to hoarseness, gen-
eralized thickening of skin and mucosae, and extra-
cutaneous features including epilepsy and
psychiatric abnormalities.2—4,9 LP is caused bymuta-
tions in the extracellular matrix protein 1 (ECM1)
gene.2 ECM1 is involved in epidermal differentia-
tion, binding of several extracellular matrix compo-
nents, in regulation of angiogenesis and in bone. Published by Elsevier Ltd. All rights reserved.
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tions have been described in individuals with LP. In
most LP patients, skin abnormalities are the first and
most prominent symptom. Here we report clinical,
neuroradiological, and molecular genetic findings in
a patient in whom mild skin changes were over-
looked and diagnosis was made only in adulthood as
a result of the occurrence of migraine and epilepsy.Figure 1 Photographs of the patient showing: (A) thick-
ened skin of the face, and (B) beaded papules along the
eyelid margins and partially missing eyelashes. The
patient also had a coloboma iridis at her left eye.Case report
A 39-year-old Belgian woman presented at our neu-
rology clinic with temporal lobe epilepsy since 5
years, and migraine without aura, fulfilling the
criteria of the international headache society
(IHS),12 since 2 years. The headache occurred
almost daily, in attacks with very rapid onset and
lasting 1 day. Her headaches were characterized by
a unilateral localization, severe pain intensity caus-
ing the patient to stay in bed, and were associated
with photo- and phonophobia. There was a positive
response to acute treatment with tryptans. She
experienced complex partial seizures and less fre-
quently secondary generalized tonic-clonic sei-
zures. The partial seizures were characterized by
reduced consciousness without automatisms or
other symptoms, and were not preceded by an aura.
After multiple trials with several anti-epileptic
drugs (AED), including valproate, lamotrigin, carba-
mazepin, phenobarbital, gabapentin and levetira-
cetam, she became seizure-free and experienced no
more headache attacks with a daily treatment of
topiramate 200 mg per day in monotherapy, after
one and a half year follow up. She had mild mental
retardation (total IQ = 71; Standard Progressive
Matices of Raven). Cognitive decline and neuropsy-
chological functioning were not investigated in this
patient, which is a limitation of the study. She
experienced recurring major depressions with sui-
cide attempts at the age of 36 and 38 years, and
severe affective disorder causing relational and
social problems since 5—10 years. Clinical neurolo-
gical examination was normal. Skin examination
showed thickened skin at the hands, elbows and
face (Fig. 1A) resulting in a limited mouth opening,
sparse hair, beaded papules along the eyelid margins
and partially missing eyelashes (Fig. 1B). These skin
changes were mild and previously unnoticed by the
patient and her environment. She had a coloboma
iridis at her left eye. She experienced hoarseness
since infancy. There was no known consanguinity in
her family and all relatives originated from Belgium.
She had four sisters, three brothers, and two sons,
all of them healthy. There was no family history of
epilepsy or migraine.Blood workup was unrevealing. A brain CTshowed
bilaterally symmetric horn-like calcifications within
the medial temporal lobes involving the hippocam-
pus and parahippocampal gyrus and amygdalae
(Fig. 2A). Gradient-echo T2*-weighted MRI showed
these lesions as bilaterally symmetric hypointense
areas immediately anterior to the temporal horns of
the lateral ventricles (Fig. 2B and C). Multiple inter-
ictal EEGs demonstrated frequent epileptiform
activity (sharp waves and spike wave complexes)
in the left temporal lobe.
We extracted DNA from peripheral blood of the
patient and her parents, after written informed
consent and local Ethical Committee’s approval.
Sequence analysis of the 10 coding exons and flank-
ing intron sequences of ECM1 in the patient revealed
a mutation in exon 7, leading to a homozygous
substitution of a C to a T at cDNA position 727
(c.727C > T), predicting a truncated protein of
242 amino acids (p.R243X). The patient’s parents
were both heterozygous for the mutation. A pyro-
sequencing assay confirmed the sequencing results,
and the mutation was absent in 92 healthy Belgian
control individuals. Paternity was confirmed. Muta-
tions were numbered relative to the ATG initiation
codon and described according to the MDI/HGVS
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Figure 2 (A) Axial non-contrast CT scan at the level of the midbrain. There are bilaterally symmetric horn-like
calcifications within the medial temporal lobes involving the amygdaloid complex. (B and C) Axial (B) and coronal (C)
gradient echo T2*-weighted MRI (FLASH, TR 800 ms, TE 15 ms) reveal bilaterally symmetric hypointense areas imme-
diately anterior to the temporal horns of the lateral ventricles. On the coronal image, the downward extension of the
calcifications into the parahippocampal gyrus and the uncinate process is clearly seen.mutation nomenclature recommendations (http://
www.hgvs.org/mutnomen/). Because ECM1 has sev-
eral splice variants, we used the longest mRNA
transcript (NCBI accession number NM_004425).Discussion
This case report illustrates that LP may show diverse
clinical features and yet remain undiagnosed for
many years, until neuropsychiatric problems and
especially epilepsy occur. This adult LP patient
presented with temporal lobe epilepsy and migraine
without aura, whereas her skin abnormalities had
not been noticed before.
In LP patients, seizures can occur as a visual or
olfactory aura, followed by loss of consciousness
with or without automatisms such as lip smacking
and facial grimacing, as de´ja`-vu sensations, rage
attacks, or behavioral disturbances, compatible
with temporal lobe epilepsy.10,11 Both partial and,
less frequently, secondarily generalized seizures can
occur, which can present at adult age or in child-
hood. The true incidence of seizures in LP is
unknown. Seizures in LP patients are reported to
be often therapy-resistant. However, after many
trials with different AED including valproate, lamo-
trigin, carbamazepin, phenobarbital, gabapentin
and levetiracetam, our patient became seizure-free
on topiramate 200 mg per day in monotherapy,
which should be considered as a possible therapy
in LP patients. In most LP cases with epilepsy, as in
our patient, EEG changes are observed. However,
these may also be present in LP patients withoutclinical signs of epilepsy. Characteristic bilaterally
symmetrical calcifications are found in the antero-
medial temporal lobes, especially of the amygdalae,
in 50—75% of LP cases over 10 years of age.10,11
Bilateral mesial temporal lobe calcifications invol-
ving the hippocampus and surrounding structures
(including amygdalae) have been described pre-
viously in LP patients with and without epilepsy.10,11
The amygdalae are engaged in processing affective
stimuli and emotional long-term memory.8,10 Our
patient suffered from a severe affective disorder
causing relational and social problems, which might
be related to dysfunction of the amygdalae. Our
patient did not experience obvious memory deficits,
however, neuropsychological tests were not per-
formed, due to refusal of the patient, which is a
limitation of the study.
Recently, itwasshownthatECM1interactswiththe
matrixmetalloproteinase 9 (MMP9).5MMP9 is a factor
related to the development of epilepsy and neurop-
sychiatric disease.14 Thus, loss of functional interac-
tion between ECM1 and MMP9 or other proteins may
play a role in the process leading to the neuro-cere-
bral abnormalities observed in our LP patient.
Epilepsy, particularly temporal lobe epilepsy, has
been described as a common manifestation of LP,
especially in combination with intracerebral calcifi-
cations, particularly in the anteromedial temporal
lobe. Clinically, our patient experienced temporal
lobe epilepsy, and epileptic activity has been
observed on EEG in the left temporal lobe, both
corresponding to the location of the calcifications
in our patient. Thus, it seems very likely that the
epilepsy in our patient is part of the Urbach—Wiethe
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observed inourpatienthasnotbeendescribedbefore
in LP patients. It remains undetermined whether
migraine is part of the LP syndrome, or rather a
co-incident finding in our patient. However, migraine
andepilepsyare linkedby their comorbidityandbyan
underlying mechanistic similarity, neuronal hyperex-
citability, which is common to both disorders.1,6 This
supports the suggestion that migraine could be part
of the clinical symptoms in our LP patient.
We identified a homozygous nonsense mutation
p.R243X in exon 7 of ECM1 which has been reported
previously.3 However, their patient was a compound
heterozygote for this mutation and an insertion
mutation (c.542insAA/p.R243X). Interestingly, their
patient experienced hoarseness and skin abnormal-
ities without any neurological symptoms. The
majority of mutations in ECM1 have been identified
in exons 6 and 7. Seven of 25 reported mutations
were located elsewhere in the gene. Mainly non-
sense, frameshift and deletion mutations have been
found, except for one patient who was a compound
heterozygote for the nonsense mutation p.W160X
and the missense mutation p.F167I in exon 6,3 and
another patient who was homozygous for the mis-
sense mutation p.F167L in exon 6.7 Mutations in
exon 7 are usually associated with a slightly milder
mucocutaneous LP phenotype, as was the case in our
patient. However, neurological symptoms such as
epilepsy do not show a clear specific genotype—
phenotype correlation.3
To conclude, lipoid proteinosis has to be consid-
ered in patients with temporal lobe epilepsy and
temporal calcifications, especially when other
symptoms like skin changes are overlooked.Acknowledgements
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